Fluperlapine

Fluperlapine
Systematic (IUPAC) name
	3-fluoro-6-(4-methylpiperazin-1-yl)-11H-dibenzo[b,e]azepine
Clinical data
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	67121-76-0
ATC code	None
PubChem	CID 49381
ChemSpider	44882
UNII	EWG253M961
ChEMBL	CHEMBL63756
Chemical data
Formula	C19H20FN3
Mol. mass	309.381 g/mol
	SMILES Fc4ccc3c(/N=C(/N1CCN(C)CC1)c2ccccc2C3)c4;
	InChI InChI=1S/C19H20FN3/c1-22-8-10-23(11-9-22)19-17-5-3-2-4-14(17)12-15-6-7-16(20)13-18(15)21-19/h2-7,13H,8-12H2,1H3 ; Key:OBWGMKKHCLHVIE-UHFFFAOYSA-N ;
(what is this?) (verify);

Fluperlapine (NB 106-689), also known as fluoroperlapine, is a tricyclic atypical antipsychotic with additional antidepressant and sedative effects. It was first synthesized in 1979, and then subsequently studied in animals and humans in 1984 and beyond,^[1] but despite demonstrating efficacy in the treatment of a variety of medical conditions including schizophrenia,^[2]^[3]^[4]^[5] psychosis associated with Parkinson's disease,^[6] depressive symptoms, and dystonia,^[7] it was never marketed.^[1] This was perhaps due to its capacity for producing potentially life-threatening agranulocytosis, similarly to clozapine,^[8] which it closely resembles both structurally and pharmacologically.

References [edit]

^ ^a ^b Ganellin, C. R.; Triggle, D. J.; Macdonald, F. (1997). Dictionary of pharmacological agents. CRC Press. p. 916. ISBN 978-0-412-46630-4. Retrieved 15 September 2011.
^ Fischer-Cornelssen, K. A. (1984). "Fluperlapine in 104 schizophrenic patients. Open multicenter trial". Arzneimittel-Forschung 34 (1A): 125–130. PMID 6145428. edit
^ Woggon, B.; Angst, J.; Bartels, M.; Heinrich, K.; Hippius, H.; Koukkou, M.; Krebs, E.; Küfferle, B. et al. (1984). "Antipsychotic efficacy of fluperlapine. An open multicenter trial". Neuropsychobiology 11 (2): 116–120. PMID 6148712. |displayauthors= suggested (help) edit
^ Dieterle, D.; Eben, E.; Einhäupl, K.; Hippius, H.; Klein, H.; Rüther, E.; Schmauß, M. (2008). "The Effect of Fluperlapine in Acute Psychotic Patients". Pharmacopsychiatry 17 (2): 57–60. doi:10.1055/s-2007-1017408. PMID 6728910. edit
^ Woggon, B.; Heinrich, K.; Küfferle, B.; Müller-Oerlinghausen, B.; Pöldinger, W.; Rüther, E.; Schied, H. W. (1984). "Results of a multicenter AMDP study with fluperlapine in schizophrenic patients". Arzneimittel-Forschung 34 (1A): 122–124. PMID 6145427. edit
^ Scholz, E.; Dichgans, J. (1985). "Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine". European archives of psychiatry and neurological sciences 235 (1): 60–64. PMID 2864254. edit
^ Pakkenberg, H.; Pedersen, B. (1985). "Medical treatment of dystonia". Psychopharmacology. Supplementum 2: 111–117. ISSN 0179-8456. OCLC 10642795. PMID 2860654. edit
^ Lai, W. G.; Gardner, I.; Zahid, N.; Uetrecht, J. P. (2000). "Bioactivation and covalent binding of hydroxyfluperlapine in human neutrophils: Implications for fluperlapine-induced agranulocytosis". Drug metabolism and disposition: the biological fate of chemicals 28 (3): 255–263. PMID 10681368. edit

[Ganellin-1] Ganellin, C. R.; Triggle, D. J.; Macdonald, F. (1997). Dictionary of pharmacological agents. CRC Press. p. 916. ISBN 978-0-412-46630-4. Retrieved 15 September 2011.

[pmid6145428-2] Fischer-Cornelssen, K. A. (1984). "Fluperlapine in 104 schizophrenic patients. Open multicenter trial". Arzneimittel-Forschung 34 (1A): 125–130. PMID 6145428. edit

[pmid6148712-3] Woggon, B.; Angst, J.; Bartels, M.; Heinrich, K.; Hippius, H.; Koukkou, M.; Krebs, E.; Küfferle, B. et al. (1984). "Antipsychotic efficacy of fluperlapine. An open multicenter trial". Neuropsychobiology 11 (2): 116–120. PMID 6148712. |displayauthors= suggested (help) edit

[pmid6728910-4] Dieterle, D.; Eben, E.; Einhäupl, K.; Hippius, H.; Klein, H.; Rüther, E.; Schmauß, M. (2008). "The Effect of Fluperlapine in Acute Psychotic Patients". Pharmacopsychiatry 17 (2): 57–60. doi:10.1055/s-2007-1017408. PMID 6728910. edit

[pmid6145427-5] Woggon, B.; Heinrich, K.; Küfferle, B.; Müller-Oerlinghausen, B.; Pöldinger, W.; Rüther, E.; Schied, H. W. (1984). "Results of a multicenter AMDP study with fluperlapine in schizophrenic patients". Arzneimittel-Forschung 34 (1A): 122–124. PMID 6145427. edit

[pmid2864254-6] Scholz, E.; Dichgans, J. (1985). "Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine". European archives of psychiatry and neurological sciences 235 (1): 60–64. PMID 2864254. edit

[pmid2860654-7] Pakkenberg, H.; Pedersen, B. (1985). "Medical treatment of dystonia". Psychopharmacology. Supplementum 2: 111–117. ISSN 0179-8456. OCLC 10642795. PMID 2860654. edit

[pmid10681368-8] Lai, W. G.; Gardner, I.; Zahid, N.; Uetrecht, J. P. (2000). "Bioactivation and covalent binding of hydroxyfluperlapine in human neutrophils: Implications for fluperlapine-induced agranulocytosis". Drug metabolism and disposition: the biological fate of chemicals 28 (3): 255–263. PMID 10681368. edit

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

Fluperlapine

See also [edit]

References [edit]

Navigation menu

Personal tools

Namespaces

Variants

Views

Actions

Search

Navigation

Interaction

Toolbox

Print/export

Languages